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Alpha-naphthylisothiocyanate (ANIT)–induced cholestatic
liver injury causes tissue factor (TF)–dependent coagulation in
mice, and TF deficiency reduces ANIT-induced liver injury.
However, the mechanism whereby TF contributes to hepatotox-
icity in this model is not known. Utilizing pharmacological and
genetic strategies, we evaluated the contribution of fibrinogen and
two distinct receptors for thrombin, protease-activated receptor-1
(PAR-1) and PAR-4, in a model of acute ANIT hepatotoxicity.
ANIT administration (60 mg/kg, po) caused a marked induction
of the genes encoding the three fibrinogen chains (a, b, and g) in
liver, an increase in plasma fibrinogen, and concurrent deposition
of thrombin-cleaved fibrin in liver. Partial depletion of circulating
fibrinogen with ancrod did not impact ANIT hepatotoxicity.
However, complete fibrin(ogen) deficiency significantly reduced
serum alanine aminotransferase activity and hepatocellular necro-
sis in ANIT-treated mice. ANIT-induced hepatocellular necrosis
was similar in PAR-12/2 mice compared with PAR-11/1 mice.
Interestingly, the progression of ANIT-induced hepatocellular
necrosis was significantly reduced in PAR-42/2 mice and by
administration of an inhibitory PAR-4 pepducin (P4Pal-10,
0.5 mg/kg, sc) to wild-type mice 8 h after ANIT treatment.
Interestingly, a distinct lesion, parenchymal-type peliosis, was also
observed in PAR-42/2 mice treated with ANIT and in mice that
were given P4Pal-10 prior to ANIT administration. The results
suggest that fibrin(ogen), but not PAR-1, contributes to the
progression of ANIT hepatotoxicity in mice. Moreover, the data
suggest a dual role for PAR-4 in ANIT hepatotoxicity, both
mediating an early protection against peliosis and contributing to
the progression of hepatocellular necrosis.
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Acute chemical-induced cholestatic liver injury can be modeled
in rodents by administration of alpha-naphthylisothiocyanate
(ANIT), which achieves micromolar levels in the bile of exposed
animals (Jean et al., 1995). This results in bile duct injury and
formation of ‘‘bile infarcts,’’ areas of periportal hepatocellular
necrosis containing dead/dying hepatocytes, bile, and inflamma-
tory cells, which have been described in detail previously (Plaa
and Priestly, 1976). Deficiency in the transport of ANIT into the
bile prevents necrosis, suggesting that the cytotoxic disruption of
intrahepatic bile ducts is critical for necrosis in this model
(Dietrich et al., 2001). In addition, several studies have shown
that extrahepatic factors including platelets and neutrophils, as
well as tissue factor (TF), the primary activator of the extrinsic
pathway of blood coagulation, contribute to necrosis progression
(Bailie et al., 1994; Kodali et al., 2006; Luyendyk et al., 2009;
Sullivan et al., 2010b).
Acute ANIT hepatotoxicity is associated with activation of
the coagulation cascade, as indicated by thrombin generation
and deposition of fibrin clots within areas of hepatocellular
necrosis. Indeed, coagulation cascade activation occurs in
numerous models of chemical-induced hepatotoxicity. TF
deficiency reduced generation of the coagulation protease
thrombin and the severity of hepatocellular necrosis in ANIT-
treated mice (Luyendyk et al., 2009). However, the mechanism
whereby the coagulation cascade contributes to the progression
of liver necrosis in this model is not known. Investigation of
the role of coagulation in hepatotoxicity is frequently limited
to examining the effect of thrombin inhibition (i.e., with
anticoagulants) on hepatotoxicity, with the exact mechanism
whereby thrombin contributes to liver injury left unanswered.
Thrombin generated by activation of the coagulation cascade
has multiple roles. Thrombin cleaves circulating fibrinogen to
fibrin monomers, which are cross-linked to form insoluble
fibrin clots. Moreover, thrombin can cleave and activate cell
surface G-protein–coupled protease-activated receptors (PARs)
to elicit intracellular signaling (Coughlin, 1999). PAR-1 and
PAR-4 are thrombin receptors expressed by nonparenchymal
cells in the liver (Copple et al., 2003; Jesmin et al., 2006). Unlike
humans, mouse platelets do not express PAR-1; rather, murine
platelets are activated by thrombin via cleavage of PAR-4
(Sambrano et al., 2001). Of importance, the involvement of fibrin
and PARs in acute ANIT hepatotoxicity has not been evaluated.
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Although the role of PAR-1 in liver fibrosis induced by
chronic liver injury has been investigated previously (Fiorucci
et al., 2004; Rullier et al., 2008; Sullivan et al., 2010a), the
role of this receptor in acute hepatotoxicity is less clear. PAR-
1–deficient mice were protected from acute acetaminophen
hepatotoxicity (Ganey et al., 2007). Activation of PAR-1
contributed to neutrophil activation in lipopolysaccharide
(LPS)-primed livers (Copple et al., 2003). However, PAR-1
deficiency does not contribute to the acute hepatotoxic effects
of other chemicals, such as carbon tetrachloride (Rullier et al.,
2008). In comparison to PAR-1, few studies have examined the
role of PAR-4 in hepatotoxicity.
Because we have shown previously that genetically reducing
coagulation limits ANIT-induced liver injury, the present
study tested the hypothesis that PAR-1 and PAR-4 signaling,
as well as fibrin clots, contribute to acute ANIT-induced
hepatotoxicity.
MATERIALS AND METHODS
Mice. Male and female mice between the ages of 8–16 weeks were used
for these studies. Male wild-type C57Bl/6J mice were purchased from The
Jackson Laboratory for studies of ancrod and P4Pal-10 administration. PAR-1/
mice (Connolly et al., 1997) and PAR-1þ/þ mice on an identical genetic
background (N8 C57Bl/6J) were maintained by homozygous breeding. Age-
matched male PAR-1þ/þ mice and PAR-1/ mice were used for experiments.
Fbga/ (Fbg/) mice (Suh et al., 1995) were kindly provided by Dr Jay Degen
(Cincinnati Children’s Hospital Medical Center, Cincinnati, OH). Female Fbg/
mice and Fbgþ/ mice were used for four independent experiments with age-
matched mice of each genotype. PAR-4/ mice (Sambrano et al., 2001) and
PAR-4þ/þ mice were maintained by homozygous breeding. Age-matched male
PAR-4þ/þ mice and PAR-4/ mice were used for experiments. Mice were
maintained in an Association for Assessment and Accreditation of Laboratory
Animal Care International-accredited facility at the University of Kansas Medical
Center. Mice were housed at an ambient temperature of 22C with alternating
12-h light/dark cycles and allowed water and rodent chow ad libitum (Teklad
8604; Harlan, Indianapolis, IN). All animal procedures were performed according
to the guidelines of the American Association for Laboratory Animal Science and
were approved by the KUMC Institutional Animal Care and Use Committee.
ANIT hepatotoxicity model and pharmacological interventions. Fasted
mice were treated with ANIT (Sigma-Aldrich, St Louis, MO) dissolved in corn
oil (60 mg/kg, po) or corn oil alone (control [vehicle] treatment) at 10 ml/kg.
Food was returned after treatment with ANIT or vehicle. For fibrinogen
depletion studies, 1.75 U ancrod/mouse (National Institute for Biological
Standards and Control, Hertfordshire, U.K.) or its vehicle (sterile saline) was
administered by ip injection 2, 12, 24, and 36 h after ANIT administration.
The PAR-4 pepducin P4pal-10 (palmitoyl-SGRRYGHALR-NH2; Genscript,
Piscataway, NJ) or its vehicle (PBS) was administered by sc injection at a dose
of 0.5 mg/kg 8 and 24 h after ANIT treatment. For select studies, an additional
dose of P4pal-10 was also given 2 h prior to ANIT. The mice were then
anesthetized using isoflurane 24 or 48 h after ANIT treatment for the collection
of blood and liver samples. Blood was collected from the caudal vena cava into
a syringe containing sodium citrate (final concentration, 0.38%), and additional
blood was collected into a syringe without anticoagulant. Plasma and serum
were collected from this blood by centrifugation. Sections of liver from the left
lateral lobe were fixed in 10% neutral-buffered formalin. The right medial lobe
was cut into a cube and affixed to a cork using optimal cutting temperature
compound and frozen for 3 min in liquid nitrogen–chilled isopentane. The
remaining liver was snap frozen in liquid nitrogen.
RNA isolation, complementary DNA synthesis, and real-time
PCR. RNA was isolated from approximately 100 mg of snap-frozen liver
using TRI reagent (Molecular Research Center, Inc., Cincinnati, OH).
Complementary DNA (cDNA) synthesis was performed using 1 lg of RNA
and a High Capacity cDNA Reverse Transcription kit (Applied Biosystems)
and MyCycler thermal cycler (Bio-Rad). Levels of Fbga, Fbgb, Fbgc, serum
amyloid A1 (SAA1), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) messenger RNA (mRNA) were determined using TaqMan gene
expression assays and TaqMan gene expression master mix (Applied
Biosystems) and a StepOnePlus (Applied Biosystems). The expression of each
mRNA was normalized relative to GAPDH expression levels and relative
expression level determined using the comparative Ct method.
Clinical chemistry, plasma fibrinogen determination, and fibrin Western
blotting. The serum activities of alanine aminotransferase (ALT) and alkaline
phosphatase (ALP) were determined using commercially available reagents
(Thermo Scientific). The concentration of bile acids in serum was determined
by using a commercial kit (Bio-Quant, San Diego, CA). Plasma fibrinogen
levels were determined using commercial reagents (Siemens Healthcare
Diagnostics, Deerfield, IL) and a STart4 coagulation analyzer (Diagnostica
Stago). Levels of fibrin in liver extracts were determined by Western blotting as
described previously (Luyendyk et al., 2009).
Histopathology. Formalin-fixed livers were subjected to routine processing,
sectioned at 5 lm, stained with hematoxylin and eosin, and evaluated by
light microscopy for the presence of hepatocellular necrosis, the features of
which we have described in detail previously (Luyendyk et al., 2009).
Three sections of liver from the left lateral lobe were evaluated from each
animal. Each section was evaluated in its entirety. Low magnification (340)
images encompassing each section were captured in a masked fashion.
Areas of hepatocellular necrosis in each image were outlined manually
using Scion imaging software by J.P.L., and the area of liver occupied by
necrotic areas (i.e., bile infarcts) was measured and compared with the total
area of liver in each image. The percentage of necrotic area, number of
lesions per 340 field, and average lesion size in square microns was
determined.
Statistics. Comparison of two groups was performed using Student’s t-test.
Data resistant to transformation to achieve a normal distribution were compared
utilizing the Mann-Whitney Rank Sum test. Comparison of three or more
groups was performed using one-way ANOVA and Student-Newman-Keul’s
post hoc test. The criterion for statistical significance was p < 0.05.
RESULTS
Induction of Fibrinogen Expression in ANIT-Induced
Cholestatic Liver Injury
Compared with vehicle-treated mice, levels of mRNAs
encoding the Fbga, Fbgb, and Fbgc genes were significantly
increased in livers of ANIT-treated mice (Figs. 1A–C). We
have shown previously that ANIT treatment activates the
coagulation cascade and causes marked deposition of fibrin
in the liver (Luyendyk et al., 2009). To this end, we
anticipated that ANIT treatment would elicit consumption of
circulating fibrinogen. In contrast and in line with induction
of fibrinogen expression in liver, ANIT treatment was
associated with a significant increase in plasma fibrinogen
concentration (Fig. 1D). Interestingly, mRNA levels of
SAA1 were dramatically increased in livers of mice treated
with ANIT (Fig. 1E).
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Effect of Fibrin(ogen) Deficiency on ANIT-Induced
Cholestatic Liver Injury
To deplete circulating fibrinogen in wild-type mice, we
utilized ancrod, which enzymatically cleaves fibrinogen.
Ancrod partially reduced plasma fibrinogen levels (Fig. 2A)
and hepatic fibrin deposition (Fig. 2B) in ANIT-treated mice.
However, depletion of fibrinogen with ancrod did not
significantly affect the increase in serum ALT activity, ALP
activity, serum bile acid levels, or liver necrosis in ANIT-
treated mice (Figs. 2C–H). Of importance, in preliminary
studies, we found that ancrod treatment reduced fibrinogen
levels in naive mice to undetectable levels (data not shown).
The induction of fibrinogen expression in ANIT-treated mice
prevented complete depletion of fibrinogen with ancrod, with
fibrinogen levels in ANIT-treated mice given ancrod re-
sembling normal physiological fibrinogen levels (i.e., compare
Figs. 1D and 2A). To this end, we utilized Fbga/ mice
(Fbg/ mice), which lack circulating fibrinogen (Suh et al.,
1995). Serum ALT activity was reduced in ANIT-treated Fbg/
mice compared with ANIT-treated Fbgþ/ mice, although this
difference did not achieve statistical significance at 48 h
(Fig. 3A). However, fibrinogen deficiency did not significantly
affect serum ALP activity or bile acid concentration in ANIT-
treated mice (Figs. 3B and 3C). Interestingly, both the number
and average size of necrotic lesions tended to be lower in ANIT-
treated Fbg/ mice compared with ANIT-treated Fbgþ/ mice,
although these differences did not achieve statistical significance
(Figs. 3D and 3E). Of importance, the overall area of necrosis
FIG. 1. Induction of fibrinogen and SAA1 expression in ANIT-treated mice. Wild-type C57Bl/6J mice were treated with vehicle (corn oil) or ANIT (60 mg/kg, po).
Hepatic (A) fbgb, (B) fbgc, and (C) fbga mRNA levels, (D) plasma fibrinogen concentration, and (E) SAA1 mRNA expression were determined 24 and 48 h later.
Levels of all biomarkers in mice given vehicle were not different between 24 and 48 h and were pooled. Data are expressed as mean ± SEM. n ¼ 5 mice per group.
*Significantly different from vehicle-treated mice.
COAGULATION AND ANIT HEPATOTOXICITY 235
induced by ANIT treatment was significantly reduced in ANIT-
treated Fbg/ mice compared with ANIT-treated Fbgþ/ mice
(Figs. 3F and 3H).
Characterization of ANIT-Induced Cholestatic Liver Injury in
PAR-1–Deficient and PAR-4–Deficient Mice
Thrombin can activate intracellular signaling via PAR-1 and
PAR-4. To this end, we evaluated the role of these PARs in
ANIT hepatotoxicity utilizing PAR-1/ mice and PAR-4/
mice. Serum ALT activity, ALP activity, and bile acid levels
were similar in PAR-1þ/þ mice and PAR-1/ mice 48 h after
ANIT treatment (Figs. 4A–C). In agreement, PAR-1 deficiency
did not affect necrosis in ANIT-treated mice (Figs. 4D–F).
Twenty-four hours after ANIT administration, serum ALT
activity was significantly increased in PAR-4/ mice
compared with PAR-4þ/þ mice (Fig. 5A). In contrast, serum
ALP activity and bile acid levels were not different between
PAR-4/ mice and PAR-4þ/þ mice at 24 or 48 h (Figs. 5B
and 5C). Interestingly, within 48 h after ANIT treatment, serum
ALT activity in PAR-4þ/þ mice achieved levels similar to
PAR-4/ mice (Fig. 5A). Minimal necrosis was observed in
ANIT-treated PAR-4þ/þ mice at 24 h (Figs. 5D–5G). In
striking contrast, significant liver injury occurred in the livers
of ANIT-treated PAR-4/ mice 24 h after ANIT treatment
(Figs. 5D–F and 5H). This injury was characterized by
periportal necrosis associated with marked accumulation of
red blood cells within the necrotic area, a unique lesion with
features resembling parenchymal-type peliosis, which also
occurred in platelet-depleted mice challenged with ANIT
(Sullivan et al., 2010b). Interestingly, in agreement with our
FIG. 2. Effect of fibrinogen depletion on ANIT-induced liver injury. ANIT-treated (60 mg/kg, po) wild-type C57Bl/6J mice were given multiple injections of
ancrod (1.75 U/mouse, ip) or PBS as described in ‘‘Materials and Methods’’ section. (A) Plasma fibrinogen levels and (B) hepatic fibrin deposition (representative
Western blot shown) were determined 48 h after ANIT administration. (C) Serum ALT, (D) ALP activity, (E) and bile acid levels were determined 24 and 48 h
after ANIT administration. For analysis of liver histopathology, the (F) average number of necrotic lesions per 340 field, (G) average lesion size, and (H)
percentage of necrotic tissue were determined as described in ‘‘Materials and Methods’’ section. Data are expressed as mean ± SEM. n ¼ 10 mice per group for
circulating biomarkers in the blood and 5 mice per group for analysis of liver histopathology. *Significantly different from ANIT-treated mice given PBS.
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previous studies (Luyendyk et al., 2009), ANIT-induced
necrosis markedly increased in the livers of PAR-4þ/þ mice
by 48 h (Figs. 5D–F and 5I). In contrast, the severity of
necrosis did not increase in PAR-4/ mice between 24 and
48 h (Figs. 5D–F and 5J), although the lesions observed at
24 h appeared to persist at 48 h (Fig. 5J). The results are
consistent with the hypothesis that PAR-4 both protects the
liver from early necrosis/hemorrhage during the early phase of
ANIT-induced cholestasis and also contributes at later times to
the progression of periportal hepatocellular necrosis.
Effect of Pharmacological Inhibition of PAR-4 on
ANIT-Induced Cholestatic Liver Injury
The whole-body PAR-4–deficient mice did not allow us to
characterize the role of PAR-4 during different phases of
ANIT-induced liver injury. To address the contribution of
PAR-4 in both the initiation and progression of ANIT-induced
cholestatic liver injury, we utilized a selective cell-permeable
peptide inhibitor of PAR-4, P4Pal-10 (Covic et al., 2002). The
dose selected for these studies has been shown previously to
inhibit PAR-4–dependent activation of mouse platelets (Covic
et al., 2002) and reduces inflammation in another murine
model (Slofstra et al., 2007). The pepducin was administered
by sc injection as this prolongs the half-life of the peptide in
rodents (Covic et al., 2007).
To test the hypothesis that PAR-4 contributes to the
progression of ANIT hepatotoxicity, we administered P4Pal-
10 by sc injection 8 h after ANIT treatment. Compared with
mice given vehicle, ANIT-induced liver injury was signifi-
cantly reduced in mice given P4Pal-10, as indicated by
a significant reduction in serum ALT activity and the area of
hepatocellular necrosis (Figs. 6A and 6D–F). Interestingly,
FIG. 3. Effect of complete fibrinogen deficiency on ANIT-induced liver injury. Fbgþ/ mice and Fbg/ mice were treated with ANIT (60 mg/kg, po), and
(A) serum ALT, (B) ALP activity, (C) and bile acid levels were determined 24 and 48 h later. For analysis of liver histopathology, the (D) average number of
necrotic lesions per 340 field, (E) average lesion size, and (F) percentage of necrotic tissue were determined as described in ‘‘Materials and Methods’’ section.
Data are expressed as mean ± SEM. n ¼ 7 Fbgþ/ mice and 5 Fbg/ mice per group at 24 h and 11 Fbgþ/ mice and 7 Fbg/ mice per group at 48 h.
*Significantly different from ANIT-treated Fbgþ/ mice. Representative photomicrographs showing hematoxylin- and eosin-stained liver sections from ANIT-
treated (G) Fbgþ/ mice and (H) ANIT-treated Fbg/ mice.
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serum ALP activity tended to be lower in P4Pal-10–treated
mice, although this change did not meet statistical signifi-
cance (Fig. 6B). Serum bile acids were significantly reduced
in P4Pal-10–treated mice given ANIT (Figs. 6B and 6C). Of
importance, in mice given pepducin in this paradigm, there
was no evidence of excessive red blood cell accumulation
within necrotic lesions compared with mice given vehicle
and ANIT (not shown). This result is consistent with an early
protective effect of PAR-4, left intact in this paradigm by
delaying administration of the PAR-4 inhibitor. In contrast
and mirroring the effect of complete PAR-4 deficiency
(Fig. 5) when P4Pal-10 was administered to mice 2 h prior to
ANIT, serum ALT activity was significantly increased at 24 h
(Fig. 7A). In 50% of the mice given P4Pal-10 prior to ANIT,
significant hemorrhage was evident within necrotic areas
(Fig. 7E), resembling changes observed in PAR-4/ mice
treated with ANIT (Fig. 5H). Interestingly, similar to PAR-
4/ mice, no changes in serum ALP activity or levels of bile
acids were observed 24 h after ANIT administration in mice
pretreated with P4Pal-10 (Figs. 7B and 7C).
DISCUSSION
Anticoagulant administration reduced the hepatotoxicity of
several xenobiotics in rodents, including LPS (Pearson et al.,
1996), monocrotaline (Copple et al., 2002), dimethylnitrosa-
mine (Fujiwara et al., 1988), and acetaminophen (Ganey et al.,
2007), as well as the ability of LPS to enhance hepatotoxicity
in xenobiotic coexposure models (Deng et al., 2009). These
studies strongly support the hypothesis that the coagulation
cascade contributes to hepatotoxic responses, but the mecha-
nism whereby thrombin promotes liver injury in these models
has not been investigated in detail. Indeed, thrombin could
contribute to hepatotoxic responses via fibrin clot formation as
well as signaling through various PARs. ANIT-induced
thrombin generation and liver injury were reduced in mice
expressing very low levels of TF (Luyendyk et al., 2009).
Elaborating on this result, we found that both fibrin(ogen) and
PAR-4, but not PAR-1, contribute to acute ANIT-induced
cholestatic liver injury in mice.
Circulating fibrinogen protein is comprised of three subunits
encoded by different genes (i.e., a, b, and c), which are
primarily expressed by the liver. In other models of
hepatotoxicity, deposition of cross-linked fibrin occurs in
conjunction with consumption of circulating fibrinogen protein
(Copple et al., 2002; Ganey et al., 2007). Of interest, in ANIT-
treated mice, fibrinogen gene expression and circulating
fibrinogen concentration increased. This increase in fibrinogen
availability could contribute to the marked fibrin deposition
within necrotic lesions in ANIT-treated mice (Luyendyk et al.,
2009). The dramatic induction of SAA1 suggests a basis for the
induction of fibrinogen in ANIT-treated mice as a component
of an acute phase response. However, the fibrinogen genes
have also been shown to be targets of the nuclear receptor
farnesoid X receptor (FXR), a bile acid receptor (Anisfeld
FIG. 4. Effect of PAR-1 deficiency on ANIT-induced liver injury. PAR-1þ/þ mice and PAR-1/ mice were treated with ANIT (60 mg/kg, po), and (A) serum
ALT, (B) ALP activity, and (C) bile acid levels were determined 48 h later. For analysis of liver histopathology, the (D) average number of necrotic lesions
per 340 field, (E) average lesion size, and (F) percentage of necrotic tissue were determined as described in ‘‘Materials and Methods’’ section. Data are expressed
as mean ± SEM. n ¼ 8 PAR-1þ/þ mice and 7 PAR-1/ mice per group.
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et al., 2005). Insofar as bile acid levels increase substantially in
the livers of ANIT-treated mice, this could be a plausible
mechanism whereby fibrinogen expression increases in this
model. Interestingly, FXR deficiency did not affect basal
fibrinogen gene expression in mice, nor did cholic acid feeding
affect Fbg gene induction in mice (Anisfeld et al., 2005).
Additional studies are needed to clarify the mechanism of
fibrinogen induction in the ANIT model, and comparison with
other models of noncholestatic liver injury may provide further
insight into the regulation of the fibrinogen genes.
FIG. 5. Effect of PAR-4 deficiency on ANIT-induced liver injury. PAR-4þ/þ mice and PAR-4/ mice were treated with ANIT (60 mg/kg, po), and (A) serum
ALT, (B) ALP activity, and (C) bile acid levels were determined 24 and 48 h later. For analysis of liver histopathology, the (D) average number of necrotic lesions
per 340 field, (E) average lesion size, and (F) percentage of necrotic tissue were determined as described in ‘‘Materials and Methods’’ section. Representative
photomicrographs of hematoxylin- and eosin-stained liver sections from ANIT-treated PAR-4þ/þ mice at (G) 24 and (I) 48 h and ANIT-treated PAR-4/ mice at
(H) 24 h and (J) 48 h are shown. Bar ¼ 10 lm. Data are expressed as mean ± SEM. n ¼ 4 mice per group at 24 h and 6 mice per group at 48 h. *Significantly
different from mice of the same genotype at 24 h. #Significantly different from ANIT-treated PAR-4þ/þ mice at that time.
COAGULATION AND ANIT HEPATOTOXICITY 239
Fibrinogen depletion with ancrod did not affect ANIT-
induced liver injury. However, ancrod administration did not
completely deplete circulating fibrinogen or prevent fibrin
deposition in ANIT-treated mice, most likely because of
parallel fibrinogen gene induction. Of interest, ANIT-induced
liver necrosis was significantly reduced in mice lacking
fibrinogen. This result is consistent with the hypothesis that
fibrin deposition contributes to ANIT hepatotoxicity in mice.
One mechanism whereby fibrin could contribute to the
progression of liver injury in this model is by causing local
hypoxia that promotes hepatocyte injury. Indeed, anticoagulant
administration has been shown to reduce liver hypoxia in
other models of xenobiotic hepatotoxicity (Copple et al.,
2006; Luyendyk et al., 2004). Alternatively, fibrin could
promote liver necrosis in ANIT-treated mice by enhancing
the recruitment or activation of inflammatory cells. Through
interactions with aIIbb3 and Mac-1 integrins, fibrin(ogen) can
direct the accumulation and activation of platelets and
neutrophils, respectively (Flick et al., 2004; Williams et al.,
1995). Indeed, both these cell types have been shown to
contribute to liver injury in ANIT-treated rodents (Bailie et al.,
1994; Kodali et al., 2006; Sullivan et al., 2010b). Of
importance, a complete depletion of platelets caused parenchy-
mal-type peliosis in ANIT-treated mice (Sullivan et al., 2010b),
and there was no evidence of peliosis or severe hemorrhage in
ANIT-treated Fbg/ mice.
Distinct from its role in generating fibrin clots, thrombin
activates intracellular signaling pathways via cleavage of
various PARs (Coughlin, 1999; Kahn et al., 1998). Whereas
PAR-1 expression was not identified on hepatocytes (Copple
FIG. 6. Effect of delayed PAR-4 inhibitor treatment on ANIT-induced liver injury. ANIT-treated (60 mg/kg, po) wild-type C57Bl/6J mice were treated with
P4Pal-10 (0.5 mg/kg, sc) or PBS 8 and 24 h after ANIT, as described in ‘‘Materials and Methods’’ section. (A) Serum ALT, (B) ALP activity, and (C) bile acid
levels were determined 48 h after ANIT administration. For analysis of liver histopathology, the (D) average number of necrotic lesions per 340 field, (E) average
lesion size, and (F) percentage of necrotic tissue were determined as described in ‘‘Materials and Methods’’ section. Representative photomicrographs of
hematoxylin- and eosin-stained liver sections from ANIT-treated mice given (G) PBS or (H) P4Pal-10 are shown. Data are expressed as mean ± SEM. n ¼ 10 mice
treated with PBS and 10 mice treated with P4Pal-10. *Significantly different from ANIT-treated mice given PBS.
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et al., 2003), hepatic nonparenchymal cells have been shown to
express PAR-1 (Copple et al., 2003; Gaca et al., 2002;
Gillibert-Duplantier et al., 2007). The cellular distribution of
PAR-4 in liver has not been extensively evaluated, although
immunohistochemical staining in one study suggested expres-
sion by Kupffer cells (Rullier et al., 2006). Of importance, the
cellular distribution of these two receptors is different in mice
and humans, with PAR-1 being the principal receptor for
thrombin on human platelets, whereas thrombin signaling
through PAR-4 is important for the activation of platelets in
mice (Sambrano et al., 2001).
Thrombin activation of PAR-1 has been shown to elicit the
expression of neutrophil chemokines (Uzonyi et al., 2006) and
PAR-1 activation promotes neutrophil-dependent hepatotox-
icity in LPS-primed livers (Copple et al., 2003), suggesting
a potential avenue for cross talk between PAR-1 signaling and
neutrophil accumulation/activation in cholestatic liver injury.
However, PAR-1/ mice were not protected from ANIT-
induced liver injury. Interestingly, a previous study showed
that a pharmacological inhibitor of PAR-1 reduced serum ALT
activity after bile duct ligation (Fiorucci et al., 2004), although
the inhibitor also prevented fibrinogen consumption, suggest-
ing inhibition of thrombin generation.
Previous work by our group and others has shown that
platelets contribute to ANIT-induced liver injury (Bailie et al.,
1994; Sullivan et al., 2010b). However, an important dichotomy
exists for the role of platelets in this model. Depleting platelets
prior to ANIT administration induced parenchymal-type
peliosis in ANIT-treated mice. In contrast, delayed inhibition
of platelets by treatment with the ADP receptor antagonist
clopidogrel (i.e., 8 h post-ANIT administration) reduced
hepatic neutrophil accumulation and necrosis but did not
cause parenchymal-type peliosis (Sullivan et al., 2010b). The
parallels between these observations and the current PAR-4
studies are intriguing. Complete PAR-4 deficiency, like
platelet depletion, caused parenchymal-type peliosis but
reduced the progression of ANIT-induced periportal necrosis,
whereas delayed administration of PAR-4 pepducin signifi-
cantly reduced the severity of necrosis. Taken together, these
results suggest two roles for PAR-4 in the ANIT model.
Initial activation of PAR-4 protects the liver by limiting
bleeding into areas of necrosis, resembling parenchymal-
type peliosis. Late activation of PAR-4 contributes to the
progression of ANIT-induced periportal necrosis. Additional
studies may reveal critical cross talk between thrombin,
platelets, and neutrophils required for both protective and
damaging processes in the livers of ANIT-treated mice.
Examples of potential lines of investigation include evaluat-
ing the role of PAR-4 in initiation of liver repair and
regeneration and in the accumulation/activation of inflam-
matory cells, such as neutrophils, which contribute to ANIT
hepatotoxicity.
FIG. 7. Effect of PAR-4 inhibitor pretreatment on ANIT-induced liver injury. ANIT-treated (60 mg/kg, po) wild-type C57Bl/6J mice were given P4Pal-10
(0.5 mg/kg, sc) or PBS 2 h prior to and 8 h after ANIT, as described in ‘‘Materials and Methods’’ section. (A) Serum ALT, (B) ALP activity, and (C) bile acid
levels were determined 24 h later. Representative photomicrographs of hematoxylin- and eosin-stained liver sections from ANIT-treated mice given (D) PBS or (E)
P4Pal-10 are shown. n ¼ 6 mice per group. *Significantly different from ANIT-treated mice given PBS.
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